Roche Applies Human Touch As Alternative To Animal Testing
Launches Institute of Human Biology
The Swiss major is looking to better predict which drug candidates are safe and most effective in patients by evolving and increasing the use of human model systems.
You may also be interested in...
The Boston-based biotech is weighing up its options as the fall-out from its failed IPF candidate casts a shadow over Galecto’s future.
Getting on the best reimbursement pathway in the US will be vital for the UK company as it moves closer to approval and taking on the established players in the chronic obstructive pulmonary disease arena.
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.